3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
27
Neoplasm Metastasis
9
Stomach Neoplasms
7
Ovarian Neoplasms
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Sarcoma
2
Salivary Gland Neoplasms
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Advanced Breast Cancer
2
Adenocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Interventions
Temozolomide
10
Specimen Handling
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
pembrolizumab
3
Bevacizumab
3
trametinib
2
Surgical Procedures, Operative
2
Radiation
2
Magnetic Resonance Imaging
2
Leukapheresis
2
Genetic Therapy
2
Fluorodeoxyglucose F18
2
Biopsy
2
vorasidenib
1
trastuzumab deruxtecan
1
ribociclib
1
regorafenib
1
olutasidenib
1
mirdametinib
1
lorlatinib
1
dabrafenib
1
apixaban
1
aflibercept
1
abexinostat
1
Vinblastine
1
Tretinoin
1
Therapies, Investigational
1
Restraint, Physical
1
Re-Irradiation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Astrocytoma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled